Cercar

01/03/2022 Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum
Jansen, WJ, Janssen, O, Tijms, BM, Vos, SJB, Ossenkoppele, R, Visser, PJ, Alcolea D., Amyloid Biomarker Study Grp. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology. 2022; 79(3)DOI:10.1001/jamaneurol.2021.5216. PMID:35099509. IF:29.000(Q1/1D).
04/10/2023 Multivariate GWAS of Alzheimer's disease CSF biomarker profiles implies GRIN2D in synaptic functioning.
Neumann A, Ohlei O, Küçükali F, Bos IJ, Timsina J, Vos S, Prokopenko D, Tijms BM, Andreasson U, Blennow K, Vandenberghe R, Scheltens P, Teunissen CE, Engelborghs S, Frisoni GB, Blin O, Richardson JC, Bordet R, Lleó A, Alcolea D, Popp J, Marsh TW, Gorijala P, Clark C, Peyratout G, Martinez-Lage P, Tainta M, Dobson RJB, Legido-Quigley C, Van Broeckhoven C, Tanzi RE, Ten Kate M, Lill CM, Barkhof F, Cruchaga C, Lovestone S, Streffer J, Zetterberg H, Visser PJ, Sleegers K, Bertram L. Multivariate GWAS of Alzheimer's disease CSF biomarker profiles implies GRIN2D in synaptic functioning.. Genome Medicine. 2023; 15(1)DOI:10.1186/s13073-023-01233-z. PMID:37794492. IF:10.400(Q1/1D).
19/09/2023 Brain hypometabolism in non-demented microtubule-associated protein tau H1 carriers with Parkinson's disease.
Gasca-Salas C, Trompeta C, López-Aguirre M, Rodríguez Rojas R, Clarimon J, Dols-Icardo O, El Bounasri S, Guida P, Mata-Marín D, Hernández-Fernández F, Marras C, García-Cañamaque L, Plaza de Las Heras I, Obeso I, Vela L, Fernández-Rodríguez B. Brain hypometabolism in non-demented microtubule-associated protein tau H1 carriers with Parkinson's disease.. JOURNAL OF NEUROIMAGING. 2023; 33(6)DOI:10.1111/jon.13156. PMID:37726927. IF:2.300(Q2/5D).
13/09/2023 CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease.
Del Campo M, Vermunt L, Peeters CFW, Sieben A, Hok-A-Hin YS, Lleó A, Alcolea D, van Nee M, Engelborghs S, van Alphen JL, Arezoumandan S, Chen-Plotkin A, Irwin DJ, van der Flier WM, Lemstra AW, Teunissen CE. CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease.. Nature Communications. 2023; 14(1)DOI:10.1038/s41467-023-41122-y. PMID:37704597. IF:14.700(Q1/1D).
17/08/2023 Brain connectivity correlates of cognitive dispersion in a healthy middle-aged population: influence of subjective cognitive complaints.
Mulet-Pons L, Solé-Padullés C, Cabello-Toscano M, Abellaneda-Pérez K, Perellón-Alfonso R, Cattaneo G, Solana Sánchez J, Alviarez-Schulze V, Bargalló N, Tormos-Muñoz JM, Pascual-Leone A, Bartrés-Faz D, Vaqué-Alcázar L. Brain connectivity correlates of cognitive dispersion in a healthy middle-aged population: influence of subjective cognitive complaints.. JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES. 2023; 78(11)DOI:10.1093/geronb/gbad114. PMID:37587033. IF:4.800(Q1/1D).
01/06/2025 On the complexity of biomarker-driven diagnoses of Alzheimer's disease
Grasso, SM, Santos-Santos, MA, Clark, AL. On the complexity of biomarker-driven diagnoses of Alzheimer's disease. Journal of Neuropsychology. 2025; 19(2)DOI:10.1111/jnp.12428. PMID:40317662. IF:1.800(Q3/6D).
24/03/2025 Potential of facial biomarkers for Alzheimer's disease and obstructive sleep apnea in Down syndrome and general population
Echeverry-Quiceno, LM, Llambrich, S, Heredia-Lidón, A, Giménez, S, Rozalem-Aranha, M, Inampudi, P, Heuzé, Y, Sevillano, X, Fortea, J, Martinez-Abadias, N, Alzheimers Dis Neuroimaging Initiative. Potential of facial biomarkers for Alzheimer's disease and obstructive sleep apnea in Down syndrome and general population. FASEB JOURNAL. 2025; 39(6)DOI:10.1096/fj.202403009R. PMID:40123509. IF:4.200(Q1/2D).
01/03/2026 Potential role of MRI to optimize clinical trial design for progressive supranuclear palsy and corticobasal degeneration
Garcia-Castro, J, Vandevrede, L, Donohue, MC, Vaqué-Alcázar, L, Rubio-Guerra, S, Selma-González, J, Heuer, HW, Morcillo-Nieto, AO, Franquesa, M, Dols-Icardo, O, Bejanin, A, Belbin, O, Fortea, J, Alcolea, D, Carmona-Iragui, M, Abdelnour, C, Barroeta, I, Santos-Santos, M, Saudinós, MBS, Sala, I, Lleó, A, Gorno-Tempini, ML, Mandelli, ML, Raman, R, Wills, AM, Barragan, E, Litvan, I, Boeve, B, Dickerson, B, Grossman, M, Huey, ED, Irwin, DJ, Pantelyat, A, Tartaglia, C, Rojas, JC, Boxer, AL, Illán-Gala, I. Potential role of MRI to optimize clinical trial design for progressive supranuclear palsy and corticobasal degeneration. JPAD-Journal of Prevention of Alzheimers Disease. 2026; 13(3)DOI:10.1016/j.tjpad.2026.100486. PMID:41581260. IF:7.800(Q1/1D).